Valuation: Laboratorio Reig Jofre SA

Market Cap 219M 0 250M 202M 189M 354M 23.56B 362M 2.43B 939M 11.64B 938M 917M 40.38B P/E 2026 *
13.5x
P/E 2027 * 22.4x
Enterprise Value 304M 0 346M 280M 262M 491M 32.67B 502M 3.36B 1.3B 16.15B 1.3B 1.27B 55.99B EV / Sales 2026 *
0.83x
EV / Sales 2027 * 0.76x
Free-Float
19.75%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 58 31/12/2005
Director of Finance/CFO - 19/12/2023
Chief Tech/Sci/R&D Officer - 31/12/2002
Director TitleAgeSince
Chairman - 30/12/2014
Director/Board Member 58 30/12/2014
Director/Board Member - 06/11/2017
Change 5-day change 1-year change 3-year change Capi.($)
+2.41%-.--% - - 250M
+7.13%+9.97%+55.80%+160.09% 1,077B
+3.99%+11.50%+67.09%+55.96% 613B
+4.20%+17.03%+38.97%+91.06% 448B
+0.99%+4.85%+28.17%+23.89% 332B
+1.82%+8.19%+40.04%+27.95% 293B
+0.22%+6.75%+31.30%+42.34% 286B
+0.73%+8.53%-27.33%-39.55% 215B
+1.56%+6.14%+29.30%+60.97% 193B
+3.26%+3.33%+15.55%+68.24% 159B
Average +2.63%+8.00%+30.99%+54.55% 401.79B
Weighted average by Cap. +3.85%+8.93%+41.75%+80.17%

Financials

2026 *2027 *
Net sales 365M 0 416M 336M 315M 590M 39.26B 603M 4.04B 1.56B 19.4B 1.56B 1.53B 67.28B 392M 0 447M 361M 338M 634M 42.16B 647M 4.34B 1.68B 20.84B 1.68B 1.64B 72.26B
Net income 16.7M 0 19.05M 15.39M 14.41M 27.02M 1.8B 27.59M 185M 71.59M 888M 71.52M 69.96M 3.08B 9.5M 0 10.83M 8.76M 8.2M 15.37M 1.02B 15.69M 105M 40.73M 505M 40.68M 39.8M 1.75B
Net Debt 84.7M 0 96.6M 78.07M 73.09M 137M 9.11B 140M 938M 363M 4.5B 363M 355M 15.62B 78.7M 0 89.76M 72.54M 67.92M 127M 8.47B 130M 872M 337M 4.18B 337M 330M 14.51B
Logo Laboratorio Reig Jofre SA
Laboratorio Reig Jofre SA, formerly Natraceutical SA, is a Spain-based company primarily engaged in the research, development, manufacturing and marketing of drugs. The Company’s activities are divided into four business divisions: Industrial Services, providing production services for third parties; Pharma, selling own pharmaceuticals under a range of brands, such as Reig Jofre, Medea, Orravan, Bioglan and Sala; Reaserch and Development (R&D) and Regulatory, including the development of indications for existing molecules, as well as generics and molecular diagnostics, among others; and Biotech, offering biopharmaceutical support services, such as analytical and process development, quality control and assurance, as well as stability studies. The Company also provides nutritional cosmetics, and food supplements, among others. It operates worldwide in Europe, Africa, the Americas, Australia and Asia through a number of subsidiaries, including Chiesi Espana SA and Oryzon Genomics SA.
Employees
-
Trader
-
Investor
Global
-
Quality
ESG MSCI
-